New initiative aims to improve chances of medicines receiving positive HTA decisions: "A unique initiative launched today by muscular dystrophy charity Duchenne UK is set to radically simplify the way necessary evidence is generated for submissions made to health technology appraisals (HTA) bodies such as the National Institute for Health and Care Excellence (NICE) and the Haute Autorité de Santé (HAS).
Launched today at the 8th World Orphan Drug Congress in Barcelona, this innovative collaboration – entitled HERCULES – will focus on medicines used to treat Duchenne muscular dystrophy (DMD). It will be the first time a group of pharmaceutical industry partners have ever collaborated to generate, share and align disease level data across an entire condition.
Although this new initiative focuses on DMD, it paves the way for similar approaches in other rare diseases, and has the potential to improve the chances of medicines in rare and orphan diseases receiving positive HTA decisions. This unique collaborative approach has been welcomed by a range of industry health economists, as well as former NICE personnel."
'via Blog this'
No comments:
Post a Comment